C1254351||Antiviral
C0025929||Mice
C1254351||Anti-enteroviral
C3665472||chemotherapeutics
C0243095||not registered so far
C0013203||drug-resistance
C0033213||problem
C3665472||chemotherapy
C0013227||drugs
C1254351||anti-enteroviral compounds
C1533734||consecutive alternating administration
C1533734||consecutive alternating administration
C1533734||consecutive alternating administration
C1515657||in vivo models
C0003065||newborn
C0025929||mice
C0042769||neurotropic
C0042776||Nancy strain
C0042769||cardiotropic (Woodruff strain) infections
C1706082||Compounds
C0014383||enterovirus
C0014383||enterovirus
C0042774||replication
C0058467||disoxaril
C0042981||VP1
C1254351||blocker
C0120447||guanidine.HCl
C0246875||2C protein
C0673446||oxoglaucine
C1533734||consecutive alternating administration
C0025929||mice
C3714514||infected
C0042776||Nancy
C0042776||Woodruff virus
C0335256||proofs
C1533734||consecutive alternating administration
C1519193||scheme
C0013203||drug resistance
C0014378||EV infections